Myovant Sciences
Myovant Sciences is a biopharmaceutical company. It works for women and for men through purpose driven science, Empowering Medicines and Transformative Advocacy company. It have three clinical programs for relugolix which consisted of five international phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis associated pain and one in men with advanced prostate cancer. The headquarters is in UK.
Sumitovant Biopharma acquired Myovant Sciences for 1.7 billion USD in 2023.